ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00385021|
Recruitment Status : Terminated
First Posted : October 6, 2006
Last Update Posted : November 2, 2007
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Neoplasms||Drug: 5-Fluorouracil, leucovorin, oxaliplatin, avastin||Phase 2|
The purpose of this study is to determine if treatment with 5-Fluorouracil, leucovorin, oxaliplatin, and Avastin will cause colorectal tumor cells to shrink or disappear. The study will also determine the safety of these drugs when given together and the quality of life of the patients who are enrolled in the study.
It is thought that these drugs will be better tolerated if they are chronomodulated, i.e., if they are given at certain times of day rather than as a continuous infusion.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer|
|Study Start Date :||October 2006|
|Actual Study Completion Date :||September 2007|
- The primary objective is to determine if the rate of adverse events among patients receiving chronoFOLFOX plus Avastin is acceptable compared to that in previous studies using the FOLFOX4 regimen. [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00385021
|United States, Oklahoma|
|Cancer Treatment Centers of America at Southwestern Regional Medical Center, Inc.|
|Tulsa, Oklahoma, United States, 74133|
|Principal Investigator:||Petra Ketterl, MD||Cancer Treatment Centers of America at Southwestern Regional Medical Center, Inc.|